Cancer Supportive Care Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (G-CSFs, ESAs, Opioids), By Region (APAC, North America, Europe, MEA), And Segment Forecasts, 2022 - 2030

May 2022 | 89 pages | ID: C190B2C0FC1EN
Grand View Research, Inc.

Abstracts

This report can be delivered to the clients within 3 Business Days

Cancer Supportive Care Drugs Market Growth & Trends

The global cancer supportive care drugs market size is expected to reach USD 12.17 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to decline at a CAGR of -1.57% from 2022 to 2030. This decline is due to factors, such as the launch of biosimilar and approval & uptake of targeted treatments for cancer, which have lesser side effects than traditional chemotherapy drugs. The growing cancer prevalence, high adoption & dependency on traditional treatments, such as chemotherapy, in the developing region, and the rising geriatric population are some of the prominent factors that drive the market growth. According to Globocan, the number of new cancer cases is expected to reach 28.4 million within the next two decades, with a rise of 47% from 2020.

In addition, in developing regions, such as Asian and African countries, due to less disposable income levels and lack of proper reimbursement scenarios, chemotherapy is the most widely preferred cancer treatment compared to other costly targeted therapies. However, the growing adoption of targeted therapies and biosimilars in Europe and the U.S. impedes the market growth. The patent expiration of blockbuster drugs, such as Amgen Inc.’s Neupogen and Neulasta and Johnson & Johnson Services, Inc.’s Procrit/Eprex, is another factor that hampers the market growth. Furthermore, the COVID-19 pandemic has had a significant impact on cancer care. There was a substantial decline in hospital visits, cancer screenings, surgeries, and therapy amid the pandemic.

However, the impact of the pandemic has declined and conditions are getting back to normal in many regions from the second quarter of 2021. Key players are addressing the opportunity of drug patient expiration and thus, are launching biosimilars in the market. The launch of biosimilars has supported expanded access to affordable care for cancer patients. For instance, in June 2020, Pfizer Inc. received the U.S. FDA approval for NYVEPRIA (pegfilgrastim-apgf), a biosimilar to Neulasta. It reduces the incidence of febrile neutropenia in patients with non-myeloid malignancies undergoing myelosuppressive anticancer medications. In November 2019, Novartis AG received the FDA approval for Ziextenzo, its biosimilar version of pegfilgrastim. The product was commercialized in Europe in 2018.

Cancer Supportive Care Drugs Market Report Highlights

• The G-CSFs (Granulocyte-colony Stimulating Factors) segment accounted for the highest share in 2021, which is expected to decline to 15.9% by 2030
• The antiemetics segment is expected to show positive growth during the forecast period due to the launch of newer drugs, such as Cinvanti, Sustol, and Varubi
• North America and other developed regional markets are expected to decline over the forecast period
• The declining sales in developed markets can be attributed to the launch & rapid uptake of multiple biosimilar & restrictions on opioid prescription

Contents

CHAPTER 1 METHODOLOGY AND SCOPE

1.1 Market Segmentation and Scope
  1.1.1 Segment Scope
  1.1.2 Regional Scope
  1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
  1.3.1 Purchased Database:
  1.3.2 Gvr’s Internal Database
  1.3.3 Secondary Sources
  1.3.4 Primary Research
  1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
  1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
  1.6.1 Commodity Flow Analysis
    1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List Of Secondary Sources
1.9 List Of Abbreviations
1.10 Objectives
  1.10.1 Objective 1
  1.10.2 Objective 2
  1.10.3 Objective 3
  1.10.4 Objective 4

CHAPTER 2 EXECUTIVE SUMMARY

2.1 Market Outlook

CHAPTER 3 CANCER SUPPORTIVE CARE DRUGS MARKET VARIABLES, TRENDS, AND SCOPE

3.1 Market Lineage Outlook
3.2 Penetration And Growth Prospect Mapping
3.3 Industry Value Chain Analysis
3.4 Regulatory Framework
3.5 Supply Demand Analysis
3.6 Covid Impact Analysis
3.7 Market Dynamics
  3.7.1 Market Driver Analysis
    3.7.1.1 Growing Cancer Prevalence And Increase In Number Of People Receiving Chemotherapy
    3.7.1.2 Large Number Of Side Effects Associated With The Cancer Treatment
  3.7.2 Market Restraint Analysis
    3.7.2.1 Rising Popularity Of Targeted Therapies For The Treatment Of Cancer In Developed Countries
    3.7.2.2 Safety Issues Associated With Supportive Care Agents
  3.7.3 Industry Opportunity Analysis
    3.7.3.1 Development Of Safer Alternatives For Erythropoiesis-Stimulating Agents And Pain Management Products And Launch Of Biosimilars
  3.7.4 Industry Challenges
    3.7.4.1 Less Developed Cancer Supportive Cancer Market In Low- And Middle-Income Countries (Lmics)
3.8 Pestel Analysis
3.9 Industry Analysis - Porter’s

CHAPTER 4 CANCER SUPPORTIVE CARE DRUGS MARKET: SEGMENT ANALYSIS, BY THERAPEUTIC CLASS, 2017 - 2030 (USD MILLION)

4.1 Cancer Supportive Care Drugs Market: Therapeutic Class Movement Analysis
4.2 G-Csfs (Granulocyte-Colony Stimulating Factors)
  4.2.1 G-Csfs (Granulocyte-Colony Stimulating Factors) Market, 2017 - 2030 (USD Million)
4.3 Esas (Erythropoiesis Stimulating Agents)
  4.3.1 Esas (Erythropoiesis Stimulating Agents) Market, 2017 - 2030 (USD Million)
4.4 Antiemetics
  4.4.1 Antiemetics Market, 2017 - 2030 (USD Million)
4.5 Bisphosphonates
  4.5.1 Bisphosphonates Market, 2017 - 2030 (USD Million)
4.6 Opioids
  4.6.1 Opioids Market, 2017 - 2030 (USD Million)
4.7 Nsaids And Others
  4.7.1 Nsaids And Others Market, 2017 - 2030 (USD Million)

CHAPTER 5 CANCER SUPPORTIVE CARE DRUGS MARKET: SEGMENT ANALYSIS, BY REGION, 2017 - 2030 (USD MILLION)

5.1 Regional Market Share Analysis, 2021 & 2030
5.2 Regional Market Snapshot
5.3 Market Size, & Forecasts, Revenue And Trend Analysis, 2021 To 2030
  5.3.1 North America
    5.3.1.1 North America Market Estimates And Forecast, 2017 - 2030 (USD Million)
    5.3.1.2 U.S.
      5.3.1.2.1 U.S. Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    5.3.1.3 Canada
      5.3.1.3.1 Canada Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    5.3.1.4 Mexico
      5.3.1.4.1 Mexico Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
  5.3.2 Europe
    5.3.2.1 Europe Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    5.3.2.2 U.K.
      5.3.2.2.1 U.K. Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    5.3.2.3 Germany
      5.3.2.3.1 Germany Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    5.3.2.4 Spain
      5.3.2.4.1 Spain Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    5.3.2.5 France
      5.3.2.5.1 France Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    5.3.2.6 Italy
      5.3.2.6.1 Italy Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    5.3.2.7 Russia
      5.3.2.7.1 Russia Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
  5.3.3 Asia Pacific
    5.3.3.1 Asia Pacific Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    5.3.3.2 Japan
      5.3.3.2.1 Japan Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    5.3.3.3 China
      5.3.3.3.1 China Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    5.3.3.4 India
      5.3.3.4.1 India Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    5.3.3.5 Australia
      5.3.3.5.1 Australia Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
  5.3.4 Latin America
    5.3.4.1 Latin America Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    5.3.4.2 Brazil
      5.3.4.2.1 Brazil Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
  5.3.5 Mea
    5.3.5.1 Mea Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)
    5.3.5.2 South Africa
      5.3.5.2.1 South Africa Cancer Supportive Care Drugs Market, 2017 - 2030 (USD Million)

CHAPTER 6 CANCER SUPPORTIVE CARE DRUGS MARKET: COMPETITIVE ANALYSIS

6.1 Recent Developments And Impact Analysis, By Key Market Participants
  6.1.1 Synergy Analysis: Major Deals And Strategic Alliances
    6.1.1.1 New Product Launches
    6.1.1.2 Mergers And Acquisitions
    6.1.1.3 Licensing Agreements
6.2 Company Categorization
  6.2.1 Innovators
  6.2.2 Market Leaders
  6.2.3 Emerging Players
  6.2.4 Heat Map Analysis
6.3 Vendor Landscape
  6.3.1 List Of Potential End-Users
  6.3.2 Key Company Market Share Analysis, 2021
  6.3.3 Consumer Behaviour Analysis
  6.3.4 Competitive Dashboard Analysis
6.4 Private Companies
  6.4.1 List Of Key Emerging Companies
6.5 Company Market Position Analysis
6.6 Company Profiles
  6.6.1 AMGEN INC.
    6.6.1.1 Company overview
    6.6.1.2 Financial Performance
    6.6.1.3 product benchmarking
    6.6.1.4 recent developments
  6.6.2 MERCK & CO.
    6.6.2.1 Company Overview
    6.6.2.2 Financial Performance
    6.6.2.3 Product benchmarking
    6.6.2.4 Recent developments
  6.6.3 JOHNSON & JOHNSON SERVICES, INC.
    6.6.3.1 Company Overview
    6.6.3.2 Financial Performance
    6.6.3.3 Product benchmarking
    6.6.3.4 Recent developments
  6.6.4 HERON THERAPEUTICS, INC.
    6.6.4.1 Company Overview
    6.6.4.2 Financial Performance
    6.6.4.3 Product benchmarking
    6.6.4.4 Recent developments
  6.6.5 NOVARTIS AG
    6.6.5.1 Company Overview
    6.6.5.2 Sandoz International GmbH
    6.6.5.3 Financial Performance
    6.6.5.4 Product benchmarking
    6.6.5.5 Recent developments
  6.6.6 GLAXOSMITHKLINE PLC. (TESARO, INC.)
    6.6.6.1 Company Overview
    6.6.6.2 Financial Performance
    6.6.6.3 Product benchmarking
    6.6.6.4 Recent developments
  6.6.7 F. HOFFMANN-LA ROCHE AG
    6.6.7.1 Company Overview
    6.6.7.2 Financial Performance
    6.6.7.3 Product benchmarking
    6.6.7.4 Recent developments
  6.6.8 HELSINN HEALTHCARE SA
    6.6.8.1 Company Overview
    6.6.8.2 Product benchmarking
    6.6.8.3 Recent developments

List Of Tables

LIST OF TABLES

TABLE 1 List of secondary sources
TABLE 2 List of Abbreviation
TABLE 3 Regulatory framework
TABLE 4 Factors influencing the demand and supply
TABLE 5 Most prevalent cancers using chemotherapy and/or radiation therapy as a treatment option (2021)
TABLE 6 Major products: G-CSF
TABLE 7 Major products: ESAs
TABLE 8 Major products: Antiemetics
TABLE 9 Major products: Bisphosphonates
TABLE 10 Major products: Opioids and non-opioids
TABLE 11 North America Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
TABLE 12 U.S. Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
TABLE 13 Canada Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
TABLE 14 Mexico Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
TABLE 15 Europe Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
TABLE 16 U.K. Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
TABLE 17 Germany Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
TABLE 18 Italy Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
TABLE 19 France Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
TABLE 20 Spain Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
TABLE 21 Russia Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
TABLE 22 Asia Pacific Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
TABLE 23 Japan Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
TABLE 24 China Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
TABLE 25 India Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
TABLE 26 Australia Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
TABLE 27 Latin America Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
TABLE 28 Brazil Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
TABLE 29 MEA Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)
TABLE 30 South Africa Cancer Supportive Care Drugs Market, By Therapeutic Class, 2017 - 2030 (USD Million)

List Of Figures

LIST OF FIGURES

FIG. 1 Cancer supportive care drugs market segmentation
FIG. 2 Market research process
FIG. 3 Information procurement
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Value-chain-based sizing & forecasting
FIG. 7 QFD modeling for market share assessment
FIG. 8 Market formulation & validation
FIG. 9 Commodity Flow Approach
FIG. 10 Market outlook (2021)
FIG. 11 Penetration and growth prospect mapping
FIG. 12 Penetration and growth prospect mapping
FIG. 13 Cancer supportive care drugs market driver impact
FIG. 14 Global population by age group, 2016, 2021, & 2027
FIG. 15 Cancer supportive care drugs market restraint impact
FIG. 16 PESTEL analysis
FIG. 17 Porter’s five forces analysis
FIG. 18 Cancer Supportive Care Drugs therapeutic class outlook: Key takeaways
FIG. 19 Cancer supportive care drugs market: Therapeutic class movement analysis (USD Million)
FIG. 20 G-CSFs (Granulocyte-colony Stimulating Factors), 2017 - 2028 (USD Million)
FIG. 21 ESAs (Erythropoiesis Stimulating Agents) market, 2017 - 2028 (USD Million)
FIG. 22 Antiemetics market, 2017 - 2028 (USD Million)
FIG. 23 Bisphosphonates market, 2017 - 2028 (USD Million)
FIG. 24 Opioids market, 2017 - 2028 (USD Million)
FIG. 25 NSAIDs and others market, 2017 - 2028 (USD Million)
FIG. 26 Regional outlook, 2021 &2030
FIG. 27 Regional marketplace: Key takeaways
FIG. 28 North America
FIG. 29 North America Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
FIG. 30 U.S.
FIG. 31 U.S. Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
FIG. 32 Canada
FIG. 33 Canada Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
FIG. 34 Mexico
FIG. 35 Mexico Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
FIG. 36 Europe
FIG. 37 Europe Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
FIG. 38 U.K.
FIG. 39 U.K. Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
FIG. 40 Germany
FIG. 41 Germany Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
FIG. 42 Spain
FIG. 43 Spain Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
FIG. 44 France
FIG. 45 France Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
FIG. 46 Italy
FIG. 47 Italy Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
FIG. 48 Russia
FIG. 49 Russia Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
FIG. 50 Asia Pacific
FIG. 51 Asia Pacific Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
FIG. 52 Japan
FIG. 53 Japan Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
FIG. 54 China
FIG. 55 China Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
FIG. 56 India
FIG. 57 India Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
FIG. 58 Australia
FIG. 59 Australia Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
FIG. 60 Latin America
FIG. 61 Latin America Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
FIG. 62 Brazil
FIG. 63 Brazil Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
FIG. 64 Middle East and Africa
FIG. 65 MEA Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million).
FIG. 66 South Africa
FIG. 67 South Africa Cancer Supportive Care Drugs market, 2017 - 2030 (USD Million)
FIG. 68 Heat map analysis
FIG. 69 Company market position analysis (2021)
FIG. 70 Consumer behavior analysis
FIG. 71 Market differentiators
FIG. 72 Company market position analysis, 2021
FIG. 73 Company market position analysis, 2021